Extracellular vesicle cross-talk in the bone marrow microenvironment: Implications in multiple myeloma

Oncotarget

Volumn 7, Issue 25, 2016, Pages 38927-38945

  Wang, Jinheng ^a   Faict, Sylvia ^a   Maes, Ken ^a   De Bruyne, Elke ^a   Van Valckenborgh, Els ^a   Schots, Rik ^b   Vanderkerken, Karin ^a   Menu, Eline ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Bone marrow microenvironment; Cross talk; Exosome; Extracellular vesicle; Multiple myeloma

Indexed keywords

ANGIOPOIETIN 1; B CELL ACTIVATING FACTOR; B7 ANTIGEN; CD147 ANTIGEN; CD38 ANTIGEN; CD40 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; FIBRONECTIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEAT SHOCK PROTEIN 70; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; SOMATOMEDIN C RECEPTOR; STAT1 PROTEIN; STAT3 PROTEIN; STROMAL CELL DERIVED FACTOR 1; SYNDECAN 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CANCER PROGNOSIS; CAPILLARY DENSITY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE RELEASE; DOWN REGULATION; EXOSOME; HUMAN; MULTIPLE MYELOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RNA SEQUENCE; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; BONE MARROW; CELL COMMUNICATION; DENDRITIC CELL; DISEASE EXACERBATION; METABOLISM; MOUSE; PATHOLOGY; PLASMA CELL;

ANIMALS; BONE MARROW; BONE MARROW CELLS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL PROLIFERATION; DENDRITIC CELLS; DISEASE PROGRESSION; EXOSOMES; EXTRACELLULAR VESICLES; HUMANS; MICE; MULTIPLE MYELOMA; PLASMA CELLS; TUMOR MICROENVIRONMENT;

EID: 84978168294     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7792     Document Type: Article

References (179)

1. Lemaire M, Deleu S, De Bruyne E, Van Valckenborgh E, Menu E and Vanderkerken K. The microenvironment and molecular biology of the multiple myeloma tumor. Adv Cancer Res. 2011; 110:19-42.
2. Fooksman DR, Vardhana S, Vasiliver-Shamis G, Liese J, Blair DA, Waite J, Sacristan C, Victora GD, Zanin-Zhorov A and Dustin ML. Functional anatomy of T cell activation and synapse formation. Annu Rev Immunol. 2010; 28:79-105.
3. Hwang I. Cell-cell communication via extracellular membrane vesicles and its role in the immune response. Mol Cells. 2013; 36(2):105-111.
4. Camussi G, Deregibus MC, Bruno S, Grange C, Fonsato V and Tetta C. Exosome/microvesicle-mediated epigenetic reprogramming of cells. Am J Cancer Res. 2011; 1(1):98-110.
5. Raposo G and Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013; 200(4):373-383.
6. Raimondo F, Morosi L, Chinello C, Magni F and Pitto M. Advances in membranous vesicle and exosome proteomics improving biological understanding and biomarker discovery. Proteomics. 2011; 11(4):709-720.
7. Johnstone RM, Adam M, Hammond JR, Orr L and Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem. 1987; 262(19):9412-9420.
8. Thery C, Zitvogel L and Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002; 2(8):569-579.
9. Kharaziha P, Ceder S, Li Q and Panaretakis T. Tumor cellderived exosomes: a message in a bottle. Biochimica et biophysica acta. 2012; 1826(1):103-111.
10. Klumperman J and Raposo G. The complex ultrastructure of the endolysosomal system. Cold Spring Harbor perspectives in biology. 2014; 6(10):a016857.
11. Stuffers S, Sem Wegner C, Stenmark H and Brech A. Multivesicular endosome biogenesis in the absence of ESCRTs. Traffic. 2009; 10(7):925-937.
12. Kowal J, Tkach M and Thery C. Biogenesis and secretion of exosomes. Current opinion in cell biology. 2014; 29:116-125.
13. Nabhan JF, Hu R, Oh RS, Cohen SN and Lu Q. Formation and release of arrestin domain-containing protein 1-mediated microvesicles (ARMMs) at plasma membrane by recruitment of TSG101 protein. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(11):4146-4151.
14. Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, Ivarsson Y, Depoortere F, Coomans C, Vermeiren E, Zimmermann P and David G. Syndecansyntenin-ALIX regulates the biogenesis of exosomes. Nature cell biology. 2012; 14(7):677-685.
15. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y and Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010; 285(23):17442-17452.
16. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, Schwille P, Brugger B and Simons M. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008; 319(5867):1244-1247.
17. Thery C, Ostrowski M and Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009; 9(8):581-593.
18. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ and Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature cell biology. 2007; 9(6):654-659.
19. Bobrie A, Colombo M, Raposo G and Thery C. Exosome secretion: molecular mechanisms and roles in immune responses. Traffic. 2011; 12(12):1659-1668.
20. Liu C, Yu S, Zinn K, Wang J, Zhang L, Jia Y, Kappes JC, Barnes S, Kimberly RP, Grizzle WE and Zhang HG. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol. 2006; 176(3):1375-1385.
21. van Balkom BW, de Jong OG, Smits M, Brummelman J, den Ouden K, de Bree PM, van Eijndhoven MA, Pegtel DM, Stoorvogel W, Wurdinger T and Verhaar MC. Endothelial cells require miR-214 to secrete exosomes that suppress senescence and induce angiogenesis in human and mouse endothelial cells. Blood. 2013; 121(19):3997-4006, S3991-3915.
22. Lee HD, Kim YH and Kim DS. Exosomes derived from human macrophages suppress endothelial cell migration by controlling integrin trafficking. Eur J Immunol. 2014; 44:1156-69.
23. Sheldon H, Heikamp E, Turley H, Dragovic R, Thomas P, Oon CE, Leek R, Edelmann M, Kessler B, Sainson RC, Sargent I, Li JL and Harris AL. New mechanism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes. Blood. 2010; 116(13):2385-2394.
24. Cai Z, Yang F, Yu L, Yu Z, Jiang L, Wang Q, Yang Y, Wang L, Cao X and Wang J. Activated T cell exosomes promote tumor invasion via Fas signaling pathway. J Immunol. 2012; 188(12):5954-5961.
25. Gu J, Qian H, Shen L, Zhang X, Zhu W, Huang L, Yan Y, Mao F, Zhao C, Shi Y and Xu W. Gastric cancer exosomes trigger differentiation of umbilical cord derived mesenchymal stem cells to carcinoma-associated fibroblasts through TGF-beta/Smad pathway. PLoS One. 2012; 7(12):e52465.
26. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, Garcia-Santos G, Ghajar C, Nitadori-Hoshino A, Hoffman C, Badal K, Garcia BA, Callahan MK, Yuan J, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012; 18(6):883-891.
27. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A and Ratajczak MZ. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia. 2006; 20(9):1487-1495.
28. Liu Y, Xiang X, Zhuang X, Zhang S, Liu C, Cheng Z, Michalek S, Grizzle W and Zhang HG. Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells. Am J Pathol. 2010; 176(5):2490-2499.
29. Jung T, Castellana D, Klingbeil P, Cuesta Hernandez I, Vitacolonna M, Orlicky DJ, Roffler SR, Brodt P and Zoller M. CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia. 2009; 11(10):1093-1105.
30. Yeo RW, Lai RC, Zhang B, Tan SS, Yin Y, Teh BJ and Lim SK. Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Advanced drug delivery reviews. 2013; 65(3):336-341.
31. Baglio SR, Rooijers K, Koppers-Lalic D, Verweij FJ, Perez Lanzon M, Zini N, Naaijkens B, Perut F, Niessen HW, Baldini N and Pegtel DM. Human bone marrow-and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species. Stem cell research & therapy. 2015; 6:127.
32. Collino F, Deregibus MC, Bruno S, Sterpone L, Aghemo G, Viltono L, Tetta C and Camussi G. Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. PLoS One. 2010; 5(7):e11803.
33. Tomasoni S, Longaretti L, Rota C, Morigi M, Conti S, Gotti E, Capelli C, Introna M, Remuzzi G and Benigni A. Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. Stem cells and development. 2013; 22(5):772-780.
34. Vallabhaneni KC, Penfornis P, Dhule S, Guillonneau F, Adams KV, Mo YY, Xu R, Liu Y, Watabe K, Vemuri MC and Pochampally R. Extracellular vesicles from bone marrow mesenchymal stem/stromal cells transport tumor regulatory microRNA, proteins, and metabolites. Oncotarget. 2015; 6(7):4953-4967. doi: 10.18632/oncotarget.3211.
35. Favaro E, Carpanetto A, Lamorte S, Fusco A, Caorsi C, Deregibus MC, Bruno S, Amoroso A, Giovarelli M, Porta M, Perin PC, Tetta C, Camussi G and Zanone MM. Human mesenchymal stem cell-derived microvesicles modulate T cell response to islet antigen glutamic acid decarboxylase in patients with type 1 diabetes. Diabetologia. 2014; 57(8):1664-1673.
36. Del Fattore A, Luciano R, Pascucci L, Goffredo BM, Giorda E, Scapaticci M, Fierabracci A and Muraca M. Immunoregulatory effects of Mesenchymal Stem Cellderived Extracellular Vesicles on T lymphocytes. Cell transplantation. 2015; 24(12):2615-27.
37. Kordelas L, Rebmann V, Ludwig AK, Radtke S, Ruesing J, Doeppner TR, Epple M, Horn PA, Beelen DW and Giebel B. MSC-derived exosomes: a novel tool to treat therapyrefractory graft-versus-host disease. Leukemia. 2014; 28(4):970-973.
38. Bian S, Zhang L, Duan L, Wang X, Min Y and Yu H. Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model. J Mol Med (Berl). 2014; 92(4):387-397.
39. He J, Wang Y, Sun S, Yu M, Wang C, Pei X, Zhu B, Wu J and Zhao W. Bone marrow stem cells-derived microvesicles protect against renal injury in the mouse remnant kidney model. Nephrology (Carlton). 2012; 17(5):493-500.
40. Ono M, Kosaka N, Tominaga N, Yoshioka Y, Takeshita F, Takahashi RU, Yoshida M, Tsuda H, Tamura K and Ochiya T. Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Science signaling. 2014; 7(332):ra63.
41. Lim PK, Bliss SA, Patel SA, Taborga M, Dave MA, Gregory LA, Greco SJ, Bryan M, Patel PS and Rameshwar P. Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res. 2011; 71(5):1550-1560.
42. Zhu W, Huang L, Li Y, Zhang X, Gu J, Yan Y, Xu X, Wang M, Qian H and Xu W. Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer letters. 2012; 315(1):28-37.
43. Bruno S, Collino F, Deregibus MC, Grange C, Tetta C and Camussi G. Microvesicles derived from human bone marrow mesenchymal stem cells inhibit tumor growth. Stem cells and development. 2013; 22(5):758-771.
44. Del Fattore A, Luciano R, Saracino R, Battafarano G, Rizzo C, Pascucci L, Alessandri G, Pessina A, Perrotta A, Fierabracci A and Muraca M. Differential effects of extracellular vesicles secreted by mesenchymal stem cells from different sources on glioblastoma cells. Expert opinion on biological therapy. 2015; 15(4):495-504.
45. Tan JK and O'Neill HC. Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity. Journal of leukocyte biology. 2005; 78(2):319-324.
46. Ganguly D, Haak S, Sisirak V and Reizis B. The role of dendritic cells in autoimmunity. Nature reviews Immunology. 2013; 13(8):566-577.
47. Chaput N, Flament C, Viaud S, Taieb J, Roux S, Spatz A, Andre F, LePecq JB, Boussac M, Garin J, Amigorena S, Thery C and Zitvogel L. Dendritic cell derived-exosomes: biology and clinical implementations. Journal of leukocyte biology. 2006; 80(3):471-478.
48. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G and Amigorena S. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med. 1998; 4(5):594-600.
49. Viaud S, Terme M, Flament C, Taieb J, Andre F, Novault S, Escudier B, Robert C, Caillat-Zucman S, Tursz T, Zitvogel L and Chaput N. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One. 2009; 4(3):e4942.
50. Simhadri VR, Reiners KS, Hansen HP, Topolar D, Simhadri VL, Nohroudi K, Kufer TA, Engert A and Pogge von Strandmann E. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS One. 2008; 3(10):e3377.
51. Thery C, Duban L, Segura E, Veron P, Lantz O and Amigorena S. Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nature immunology. 2002; 3(12):1156-1162.
52. Gehrmann U, Hiltbrunner S, Georgoudaki AM, Karlsson MC, Naslund TI and Gabrielsson S. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with alpha-galactosylceramide on exosomes. Cancer Res. 2013; 73(13):3865-3876.
53. Qazi KR, Gehrmann U, Domange Jordo E, Karlsson MC and Gabrielsson S. Antigen-loaded exosomes alone induce Th1-type memory through a B-cell-dependent mechanism. Blood. 2009; 113(12):2673-2683.
54. Naslund TI, Gehrmann U, Qazi KR, Karlsson MC and Gabrielsson S. Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity. J Immunol. 2013; 190(6):2712-2719.
55. Utsugi-Kobukai S, Fujimaki H, Hotta C, Nakazawa M and Minami M. MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells. Immunology letters. 2003; 89(2-3):125-131.
56. Bu N, Wu HQ, Zhang GL, Zhan SQ, Zhang R, Fan QY, Li YL, Zhai YF and Ren HW. Immature dendritic cell exosomes suppress experimental autoimmune myasthenia gravis. Journal of neuroimmunology. 2015; 285:71-75.
57. Yang X, Meng S, Jiang H, Zhu C and Wu W. Exosomes derived from immature bone marrow dendritic cells induce tolerogenicity of intestinal transplantation in rats. The Journal of surgical research. 2011; 171(2):826-832.
58. Li X, Li JJ, Yang JY, Wang DS, Zhao W, Song WJ, Li WM, Wang JF, Han W, Zhang ZC, Yu Y, Cao DY and Dou KF. Tolerance induction by exosomes from immature dendritic cells and rapamycin in a mouse cardiac allograft model. PLoS One. 2012; 7(8):e44045.
59. Peche H, Heslan M, Usal C, Amigorena S and Cuturi MC. Presentation of donor major histocompatibility complex antigens by bone marrow dendritic cell-derived exosomes modulates allograft rejection. Transplantation. 2003; 76(10):1503-1510.
60. Peche H, Renaudin K, Beriou G, Merieau E, Amigorena S and Cuturi MC. Induction of tolerance by exosomes and short-term immunosuppression in a fully MHCmismatched rat cardiac allograft model. American journal of transplantation. 2006; 6(7):1541-1550.
61. Veron P, Segura E, Sugano G, Amigorena S and Thery C. Accumulation of MFG-E8/lactadherin on exosomes from immature dendritic cells. Blood cells, molecules & diseases. 2005; 35(2):81-88.
62. Miksa M, Wu R, Dong W, Das P, Yang D and Wang P. Dendritic cell-derived exosomes containing milk fat globule epidermal growth factor-factor VIII attenuate proinflammatory responses in sepsis. Shock. 2006; 25(6):586-593.
63. Kim SH, Lechman ER, Bianco N, Menon R, Keravala A, Nash J, Mi Z, Watkins SC, Gambotto A and Robbins PD. Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J Immunol. 2005; 174(10):6440-6448.
64. Yang X, Meng S, Jiang H, Chen T and Wu W. Exosomes derived from interleukin-10-treated dendritic cells can inhibit trinitrobenzene sulfonic acid-induced rat colitis. Scandinavian journal of gastroenterology. 2010; 45(10):1168-1177.
65. Kim SH, Bianco N, Menon R, Lechman ER, Shufesky WJ, Morelli AE and Robbins PD. Exosomes derived from genetically modified DC expressing FasL are antiinflammatory and immunosuppressive. Molecular therapy. 2006; 13(2):289-300.
66. Kim SH, Bianco NR, Shufesky WJ, Morelli AE and Robbins PD. Effective treatment of inflammatory disease models with exosomes derived from dendritic cells genetically modified to express IL-4. J Immunol. 2007; 179(4):2242-2249.
67. Bianco NR, Kim SH, Ruffner MA and Robbins PD. Therapeutic effect of exosomes from indoleamine 2, 3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. Arthritis and rheumatism. 2009; 60(2):380-389.
68. Quah BJ and O'Neill HC. The immunogenicity of dendritic cell-derived exosomes. Blood cells, molecules & diseases. 2005; 35(2):94-110.
69. Morelli AE. The immune regulatory effect of apoptotic cells and exosomes on dendritic cells: its impact on transplantation. American journal of transplantation. 2006; 6(2):254-261.
70. Cronemberger-Andrade A, Aragao-Franca L, de Araujo CF, Rocha VJ, Borges-Silva Mda C, Figueira CP, Oliveira PR, de Freitas LA, Veras PS and Pontes-de-Carvalho L. Extracellular vesicles from Leishmania-infected macrophages confer an anti-infection cytokine-production profile to naive macrophages. PLoS neglected tropical diseases. 2014; 8(9):e3161.
71. Giri PK and Schorey JS. Exosomes derived from M. Bovis BCG infected macrophages activate antigen-specific CD4+ and CD8+ T cells in vitro and in vivo. PLoS One. 2008; 3(6):e2461.
72. Singh PP, Smith VL, Karakousis PC and Schorey JS. Exosomes isolated from mycobacteria-infected mice or cultured macrophages can recruit and activate immune cells in vitro and in vivo. J Immunol. 2012; 189(2):777-785.
73. Singh PP, LeMaire C, Tan JC, Zeng E and Schorey JS. Exosomes released from M. tuberculosis infected cells can suppress IFN-gamma mediated activation of naive macrophages. PLoS One. 2011; 6(4):e18564.
74. Skokos D, Le Panse S, Villa I, Rousselle JC, Peronet R, David B, Namane A and Mecheri S. Mast cell-dependent B and T lymphocyte activation is mediated by the secretion of immunologically active exosomes. J Immunol. 2001; 166(2):868-876.
75. Skokos D, Le Panse S, Villa I, Rousselle JC, Peronet R, Namane A, David B and Mecheri S. Nonspecific B and T cell-stimulatory activity mediated by mast cells is associated with exosomes. International archives of allergy and immunology. 2001; 124(1-3):133-136.
76. Martin PJ, Haren N, Ghali O, Clabaut A, Chauveau C, Hardouin P and Broux O. Adipogenic RNAs are transferred in osteoblasts via bone marrow adipocytes-derived extracellular vesicles (EVs). BMC cell biology. 2015; 16:10.
77. Kahlert C and Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl). 2013; 91(4):431-437.
78. Milane L, Singh A, Mattheolabakis G, Suresh M and Amiji MM. Exosome mediated communication within the tumor microenvironment. J Control Release. 2015; 219:278-94.
79. Atay S and Godwin AK. Tumor-derived exosomes: A message delivery system for tumor progression. Commun Integr Biol. 2014; 7(1):e28231.
80. Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, Hicklin DJ, Zhu Z, Witte L, Crystal RG, Moore MA and Rafii S. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med. 2001; 193(9):1005-1014.
81. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, Bosch-Marce M, Masuda H, Losordo DW, Isner JM and Asahara T. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 2003; 107(9):1322-1328.
82. Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H, Muguruma Y, Tsuboi K, Itabashi Y, Ikeda Y, Ogawa S, Okano H, Hotta T, Ando K and Fukuda K. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood. 2004; 104(12):3581-3587.
83. De Veirman K, Van Valckenborgh E, Lahmar Q, Geeraerts X, De Bruyne E, Menu E, Van Riet I, Vanderkerken K and Van Ginderachter JA. Myeloid-derived suppressor cells as therapeutic target in hematological malignancies. Front Oncol. 2014; 4:349.
84. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ and Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicincyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009; 58(1):49-59.
85. Gorgun GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, Raje N, Munshi NC, Richardson PG and Anderson KC. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013; 121(15):2975-2987.
86. Fremder E, Munster M, Aharon A, Miller V, Gingis-Velitski S, Voloshin T, Alishekevitz D, Bril R, Scherer SJ, Loven D, Brenner B and Shaked Y. Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: a process regulated by osteopontin. Int J Cancer. 2014; 135(2):270-281.
87. Munster M, Fremder E, Miller V, Ben-Tsedek N, Davidi S, Scherer SJ and Shaked Y. Anti-VEGF-A affects the angiogenic properties of tumor-derived microparticles. PLoS One. 2014; 9(4):e95983.
88. Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K and Ohyashiki JH. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 2014; 124(25):3748-3757.
89. Umezu T, Ohyashiki K, Kuroda M and Ohyashiki JH. Leukemia cell to endothelial cell communication via exosomal miRNAs. Oncogene. 2013; 32(22):2747-2755.
90. Tadokoro H, Umezu T, Ohyashiki K, Hirano T and Ohyashiki JH. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J Biol Chem. 2013; 288(48):34343-34351.
91. Corrado C, Flugy AM, Taverna S, Raimondo S, Guggino G, Karmali R, De Leo G and Alessandro R. Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis. PLoS One. 2012; 7(8):e42310.
92. Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HM, Signori E, Honoki K, Georgakilas AG, Amin A, Helferich WG, Boosani CS, et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015; 35 Suppl:S185-98.
93. Xiang X, Poliakov A, Liu C, Liu Y, Deng ZB, Wang J, Cheng Z, Shah SV, Wang GJ, Zhang L, Grizzle WE, Mobley J and Zhang HG. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer. 2009; 124(11):2621-2633.
94. Yu S, Liu C, Su K, Wang J, Liu Y, Zhang L, Li C, Cong Y, Kimberly R, Grizzle WE, Falkson C and Zhang HG. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol. 2007; 178(11):6867-6875.
95. Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, Boireau W, Rouleau A, Simon B, Lanneau D, De Thonel A, Multhoff G, Hamman A, Martin F, Chauffert B, Solary E, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloidderived suppressor cells. J Clin Invest. 2010; 120(2):457-471.
96. Madera L, Greenshields A, Coombs MR and Hoskin DW. 4T1 Murine Mammary Carcinoma Cells Enhance Macrophage-Mediated Innate Inflammatory Responses. PLoS One. 2015; 10(7):e0133385.
97. Marton A, Vizler C, Kusz E, Temesfoi V, Szathmary Z, Nagy K, Szegletes Z, Varo G, Siklos L, Katona RL, Tubak V, Howard OM, Duda E, Minarovits J and Buzas K. Melanoma cell-derived exosomes alter macrophage and dendritic cell functions in vitro. Immunology letters. 2012; 148(1):34-38.
98. Bretz NP, Ridinger J, Rupp AK, Rimbach K, Keller S, Rupp C, Marme F, Umansky L, Umansky V, Eigenbrod T, Sammar M and Altevogt P. Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling. J Biol Chem. 2013; 288(51):36691-36702.
99. Ma B, Jiang H, Jia J, Di L, Song G, Yu J, Zhu Y, Lu Z, Wang X, Zhou X and Ren J. Murine bone marrow stromal cells pulsed with homologous tumor-derived exosomes inhibit proliferation of liver cancer cells. Clinical & translational oncology. 2012; 14(10):764-773.
100. Corrado C, Raimondo S, Saieva L, Flugy AM, De Leo G and Alessandro R. Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an interleukin 8-dependent survival of leukemia cells. Cancer letters. 2014; 348(1-2):71-76.
101. Chowdhury R, Webber JP, Gurney M, Mason MD, Tabi Z and Clayton A. Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and proinvasive myofibroblasts. Oncotarget. 2015; 6(2):715-731. doi: 10.18632/oncotarget.2711.
102. Haga H, Yan IK, Takahashi K, Wood J, Zubair A and Patel T. Tumour cell-derived extracellular vesicles interact with mesenchymal stem cells to modulate the microenvironment and enhance cholangiocarcinoma growth. Journal of extracellular vesicles. 2015; 4:24900.
103. Paggetti J, Haderk F, Seiffert M, Janji B, Distler U, Ammerlaan W, Kim YJ, Adam J, Lichter P, Solary E, Berchem G and Moussay E. Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood. 2015; 126(9):1106-1117.
104. Abdi J, Chen G and Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget. 2013; 4(12):2186-2207. doi: 10.18632/oncotarget.1497.
105. Munshi NC and Anderson KC. New strategies in the treatment of multiple myeloma. Clin Cancer Res. 2013; 19(13):3337-3344.
106. Taylor DD and Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008; 110(1):13-21.
107. Ghosh AK, Secreto CR, Knox TR, Ding W, Mukhopadhyay D and Kay NE. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood. 2010; 115(9):1755-1764.
108. Di Noto G, Paolini L, Zendrini A, Radeghieri A, Caimi L and Ricotta D. C-src enriched serum microvesicles are generated in malignant plasma cell dyscrasia. PLoS One. 2013; 8(8):e70811.
109. Caivano A, Laurenzana I, De Luca L, La Rocca F, Simeon V, Trino S, D'Auria F, Traficante A, Maietti M, Izzo T, D'Arena G, Mansueto G, Pietrantuono G, Laurenti L, Musto P and Del Vecchio L. High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders. Tumour Biol. 2015; 36:9739-52.
110. Quarona V, Ferri V, Chillemi A, Bolzoni M, Mancini C, Zaccarello G, Roato I, Morandi F, Marimpietri D, Faccani G, Martella E, Pistoia V, Giuliani N, Horenstein AL and Malavasi F. Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. Annals of the New York Academy of Sciences. 2015; 1335:10-22.
111. Benameur T, Chappard D, Fioleau E, Andriantsitohaina R, Martinez MC, Clere N and Marchand-Libouban H. Plasma cells release membrane microparticles in a mouse model of multiple myeloma. Micron. 2013; 54-55:75-81.
112. Di Noto G, Chiarini M, Paolini L, Mazzoldi EL, Giustini V, Radeghieri A, Caimi L and Ricotta D. Immunoglobulin Free Light Chains and GAGs Mediate Multiple Myeloma Extracellular Vesicles Uptake and Secondary NfkappaB Nuclear Translocation. Front Immunol. 2014; 5:517.
113. Thompson CA, Purushothaman A, Ramani VC, Vlodavsky I and Sanderson RD. Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J Biol Chem. 2013; 288(14):10093-10099.
114. Manier S, Avet-Loiseau H, Campigotto F, Salem K, Huynh D, Glavey S, Sacco A, Roccaro AM, Minvielle S, Moreau P, Facon T, Leleu X, Weller E and Ghobrial I. Circulating Exosomal microRNAs Are Prognostic Markers in Multiple Myeloma. Blood, 57th ASH Annual Meeting. 2015; 126 (23):1770.
115. Seckinger A, Meissner T, Moreaux J, Benes V, Hillengass J, Castoldi M, Zimmermann J, Ho AD, Jauch A, Goldschmidt H, Klein B and Hose D. miRNAs in multiple myeloma-a survival relevant complex regulator of gene expression. Oncotarget. 2015; 6(36):39165-39183. doi: 10.18632/oncotarget.5381.
116. Chen B, Morgan G, Barlogie B and Epstein J. Specific Exosomal microRNA Are Differentially Expressed Between High and Low-Risk Myeloma Suggesting They Are Pathogenically Important. Blood, 57th ASH Annual Meeting. 2015; 126 (23): 4189.
117. Harshman SW, Canella A, Ciarlariello PD, Rocci A, Agarwal K, Smith EM, Talabere T, Efebera YA, Hofmeister CC, Benson DM, Jr., Paulaitis ME, Freitas MA and Pichiorri F. Characterization of multiple myeloma vesicles by label-free relative quantitation. Proteomics. 2013; 13(20):3013-3029.
118. Arendt BK, Walters DK, Wu X, Tschumper RC and Jelinek DF. Multiple myeloma dell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation. Oncotarget. 2014; 5(14):5686-5699. doi: 10.18632/oncotarget.2159.
119. Liu Y, Zhu XJ, Zeng C, Wu PH, Wang HX, Chen ZC and Li QB. Microvesicles secreted from human multiple myeloma cells promote angiogenesis. Acta Pharmacol Sin. 2014; 35(2):230-238.
120. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F and Dammacco F. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994; 87(3):503-508.
121. Bhatti SS, Kumar L, Dinda AK and Dawar R. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters. Am J Hematol. 2006; 81(9):649-656.
122. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ and Greipp PR. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res. 2002; 8(7):2210-2216.
123. Vacca A, Ribatti D, Roccaro AM, Ria R, Palermo L and Dammacco F. Bone marrow angiogenesis and plasma cell angiogenic and invasive potential in patients with active multiple myeloma. Acta Haematol. 2001; 106(4):162-169.
124. Ria R, Roccaro AM, Merchionne F, Vacca A, Dammacco F and Ribatti D. Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia. 2003; 17(10):1961-1966.
125. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, Greipp PR and Rajkumar SV. Expression of VEGF and its receptors by myeloma cells. Leukemia. 2003; 17(10):2025-2031.
126. Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, Mancini C, Bonomini S, Lunghi P, Hojden M, Genestreti G, Svaldi M, Coser P, Fattori PP, Sammarelli G, Gazzola GC, Bataille R, et al. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood. 2003; 102(2):638-645.
127. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001; 15(12):1950-1961.
128. Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A, Mahtouk K, Hillengass J, Reme T, De Vos J, Hundemer M, Condomines M, Bertsch U, Rossi JF, Jauch A, Klein B, et al. Induction of angiogenesis by normal and malignant plasma cells. Blood. 2009; 114(1):128-143.
129. Colla S, Storti P, Donofrio G, Todoerti K, Bolzoni M, Lazzaretti M, Abeltino M, Ippolito L, Neri A, Ribatti D, Rizzoli V, Martella E and Giuliani N. Low bone marrow oxygen tension and hypoxia-inducible factor-1alpha overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia. 2010; 24(11):1967-1970.
130. Storti P, Bolzoni M, Donofrio G, Airoldi I, Guasco D, Toscani D, Martella E, Lazzaretti M, Mancini C, Agnelli L, Patrene K, Maiga S, Franceschi V, Colla S, Anderson J, Neri A, et al. Hypoxia-inducible factor (HIF)-1alpha suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia. 2013; 27(8):1697-1706.
131. Purushothaman A, Bandari SK, Liu J, Mobley JA, Brown EE and Sanderson RD. Fibronectin on the surface of myeloma cell-derived exosomes mediates exosome-cell interactions. J Biol Chem. 2015.
132. Hameed A, Brady JJ, Dowling P, Clynes M and O'Gorman P. Bone disease in multiple myeloma: pathophysiology and management. Cancer Growth Metastasis. 2014; 7:33-42.
133. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, Kido S, Oshima T, Shibata H, Ozaki S, Inoue D and Matsumoto T. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood. 2004; 104(8):2484-2491.
134. Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B and Epstein J. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 2004; 64(6):2016-2023.
135. Abe M, Kido S, Hiasa M, Nakano A, Oda A, Amou H and Matsumoto T. BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACIFc treatment in patients with multiple myeloma. Leukemia. 2006; 20(7):1313-1315.
136. Raimondi L, De Luca A, Amodio N, Manno M, Raccosta S, Taverna S, Bellavia D, Naselli F, Fontana S, Schillaci O, Giardino R, Fini M, Tassone P, Santoro A, De Leo G, Giavaresi G, et al. Involvement of multiple myeloma cellderived exosomes in osteoclast differentiation. Oncotarget. 2015; 6(15):13772-13789. doi: 10.18632/oncotarget.3830.
137. Andre F, Schartz NE, Chaput N, Flament C, Raposo G, Amigorena S, Angevin E and Zitvogel L. Tumor-derived exosomes: a new source of tumor rejection antigens. Vaccine. 2002; 20 Suppl 4:A28-31.
138. Natasha G, Gundogan B, Tan A, Farhatnia Y, Wu W, Rajadas J and Seifalian AM. Exosomes as immunotheranostic nanoparticles. Clin Ther. 2014; 36(6):820-829.
139. Tran TH, Mattheolabakis G, Aldawsari H and Amiji M. Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases. Clin Immunol. 2015.
140. Hao S, Bai O, Yuan J, Qureshi M and Xiang J. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes. Cell Mol Immunol. 2006; 3(3):205-211.
141. Bu N, Wu H, Sun B, Zhang G, Zhan S, Zhang R and Zhou L. Exosome-loaded dendritic cells elicit tumorspecific CD8+ cytotoxic T cells in patients with glioma. J Neurooncol. 2011; 104(3):659-667.
142. Yao Y, Chen L, Wei W, Deng X, Ma L and Hao S. Tumor cell-derived exosome-targeted dendritic cells stimulate stronger CD8+ CTL responses and antitumor immunities. Biochem Biophys Res Commun. 2013; 436(1):60-65.
143. Xie Y, Bai O, Zhang H, Li W and Xiang J. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity. Cancer Biother Radiopharm. 2010; 25(1):21-28.
144. Xie Y, Bai O, Zhang H, Yuan J, Zong S, Chibbar R, Slattery K, Qureshi M, Wei Y, Deng Y and Xiang J. Membranebound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL-and NK-mediated antitumour immunity than exosomes released from heatshocked tumour cells expressing cytoplasmic HSP70. J Cell Mol Med. 2010; 14(11):2655-2666.
145. Ribatti D, Moschetta M and Vacca A. Microenvironment and multiple myeloma spread. Thromb Res. 2014; 133 Suppl 2:S102-106.
146. Cohen K, Flint N, Shalev S, Erez D, Baharal T, Davis PJ, Hercbergs A, Ellis M and Ashur-Fabian O. Thyroid hormone regulates adhesion, migration and matrix metalloproteinase 9 activity via alphavbeta3 integrin in myeloma cells. Oncotarget. 2014; 5(15):6312-6322. doi: 10.18632/oncotarget.2205.
147. Mahindra A, Hideshima T and Anderson KC. Multiple myeloma: biology of the disease. Blood Rev. 2010; 24 Suppl 1:S5-11.
148. Garcia-Gomez A, De Las Rivas J, Ocio EM, Diaz-Rodriguez E, Montero JC, Martin M, Blanco JF, Sanchez-Guijo FM, Pandiella A, San Miguel JF and Garayoa M. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease. Oncotarget. 2014; 5(18):8284-8305. doi: 10.18632/oncotarget.2058.
149. Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, Benner A, Hundemer M, Reme T, Shaughnessy JD, Jr., Barlogie B, Bertsch U, Hillengass J, Ho AD, Pantesco V, Jauch A, De Vos J, et al. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene. 2009; 28(44):3866-3879.
150. Mahtouk K, Moreaux J, Hose D, Reme T, Meissner T, Jourdan M, Rossi JF, Pals ST, Goldschmidt H and Klein B. Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays. BMC cancer. 2010; 10:198.
151. Fuhler GM, Baanstra M, Chesik D, Somasundaram R, Seckinger A, Hose D, Peppelenbosch MP and Bos NA. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells. Experimental cell research. 2010; 316(11):1816-1828.
152. Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E, Anderson KC, Scadden DT and Ghobrial IM. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013; 123(4):1542-1555.
153. Wang J, Hendrix A, Hernot S, Lemaire M, De Bruyne E, Van Valckenborgh E, Lahoutte T, De Wever O, Vanderkerken K and Menu E. Bone marrow stromal cellderived exosomes as communicators in drug resistance in multiple myeloma cells. Blood. 2014; 124(4):555-566.
154. Wang J, De Veirman K, De Beule N, Maes K, De Bruyne E, Van Valckenborgh E, Vanderkerken K and Menu E. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells. Oncotarget. 2015; 6(41):43992-4004. doi: 10.18632/oncotarget.6083.
155. Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, Dey BR, Somaiya P, Mills H, Campigotto F, Weller E, Joyce R, Levine JD, Tzachanis D, Richardson P, Laubach J, et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013; 19(13):3640-3648.
156. Hobo W, Strobbe L, Maas F, Fredrix H, Greupink-Draaisma A, Esendam B, de Witte T, Preijers F, Levenga H, van Rees B, Raymakers R, Schaap N and Dolstra H. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Cancer Immunol Immunother. 2013; 62(8):1381-1392.
157. Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, Wu Z, Joyce R, Levine JD, Dombagoda D, Yuan YE, Francoeur K, Fitzgerald D, Richardson P, Weller E, Anderson K, et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011; 117(2):393-402.
158. Batchu RB, Moreno AM, Szmania SM, Bennett G, Spagnoli GC, Ponnazhagan S, Barlogie B, Tricot G and van Rhee F. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. Cancer Res. 2005; 65(21):10041-10049.
159. van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, Batchu RB, Moreno A, Spagnoli G, Shaughnessy J and Tricot G. NY-ESO-1 is highly expressed in poorprognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005; 105(10):3939-3944.
160. Rollig C, Schmidt C, Bornhauser M, Ehninger G, Schmitz M and Auffermann-Gretzinger S. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells. J Immunother. 2011; 34(1):100-106.
161. Lacy MQ, Mandrekar S, Dispenzieri A, Hayman S, Kumar S, Buadi F, Dingli D, Litzow M, Wettstein P, Padley D, Kabat B, Gastineau D, Rajkumar SV and Gertz MA. Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. Am J Hematol. 2009; 84(12):799-802.
162. Yao Y, Wei W, Sun J, Chen L, Deng X, Ma L and Hao S. Proteomic analysis of exosomes derived from human lymphoma cells. European journal of medical research. 2015; 20:8.
163. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, Angevin E, Amigorena S and Zitvogel L. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. 2001; 7(3):297-303.
164. Narita M, Kanda T, Abe T, Uchiyama T, Iwafuchi M, Zheng Z, Liu A, Kaifu T, Kosugi S, Minagawa M, Itoh K and Takahashi M. Immune responses in patients with esophageal cancer treated with SART1 peptide-pulsed dendritic cell vaccine. International journal of oncology. 2015; 46(4):1699-1709.
165. Escudier B, Dorval T, Chaput N, Andre F, Caby MP, Novault S, Flament C, Leboulaire C, Borg C, Amigorena S, Boccaccio C, Bonnerot C, Dhellin O, Movassagh M, Piperno S, Robert C, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. Journal of translational medicine. 2005; 3(1):10.
166. Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A, Hsu DH, Le Pecq JB and Lyerly HK. A phase I study of dexosome immunotherapy in patients with advanced nonsmall cell lung cancer. Journal of translational medicine. 2005; 3(1):9.
167. Kunigelis KE and Graner MW. The Dichotomy of Tumor Exosomes (TEX) in Cancer Immunity: Is It All in the ConTEXt? Vaccines. 2015; 3(4):1019-1051.
168. Oksvold MP, Kullmann A, Forfang L, Kierulf B, Li M, Brech A, Vlassov AV, Smeland EB, Neurauter A and Pedersen KW. Expression of B-cell surface antigens in subpopulations of exosomes released from B-cell lymphoma cells. Clin Ther. 2014; 36(6):847-862 e841.
169. Aung T, Chapuy B, Vogel D, Wenzel D, Oppermann M, Lahmann M, Weinhage T, Menck K, Hupfeld T, Koch R, Trumper L and Wulf GG. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(37):15336-15341.
170. Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, Morelli D, Villa A, Della Mina P, Menard S, Filipazzi P, Rivoltini L, Tagliabue E and Pupa SM. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. Journal of cellular physiology. 2012; 227(2):658-667.
171. Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C, Gonzalez S, Sanchez-Cabo F, Gonzalez MA, Bernad A and Sanchez-Madrid F. Unidirectional transfer of microRNAloaded exosomes from T cells to antigen-presenting cells. Nature communications. 2011; 2:282.
172. Longatti A, Boyd B and Chisari FV. Virion-independent transfer of replication-competent hepatitis C virus RNA between permissive cells. Journal of virology. 2015; 89(5):2956-2961.
173. Lyu L, Wang H, Li B, Qin Q, Qi L, Nagarkatti M, Nagarkatti P, Janicki JS, Wang XL and Cui T. A critical role of cardiac fibroblast-derived exosomes in activating renin angiotensin system in cardiomyocytes. Journal of molecular and cellular cardiology. 2015; 89(Pt B):268-279.
174. Marleau AM, Chen CS, Joyce JA and Tullis RH. Exosome removal as a therapeutic adjuvant in cancer. Journal of translational medicine. 2012; 10:134.
175. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A and Rak J. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nature cell biology. 2008; 10(5):619-624.
176. Di Vizio D, Kim J, Hager MH, Morello M, Yang W, Lafargue CJ, True LD, Rubin MA, Adam RM, Beroukhim R, Demichelis F and Freeman MR. Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 2009; 69(13):5601-5609.
177. Antonyak MA, Li B, Boroughs LK, Johnson JL, Druso JE, Bryant KL, Holowka DA and Cerione RA. Cancer cell derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(12):4852-4857.
178. Lee TH, Chennakrishnaiah S, Audemard E, Montermini L, Meehan B and Rak J. Oncogenic ras-driven cancer cell vesiculation leads to emission of double-stranded DNA capable of interacting with target cells. Biochem Biophys Res Commun. 2014; 451(2):295-301.
179. Al-Nedawi K, Meehan B, Kerbel RS, Allison AC and Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(10):3794-3799.